Juvmo Patent Expiration

Juvmo is a drug owned by Abbvie Inc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Juvmo's patents will be open to challenges from 25 September, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 23, 2034. Details of Juvmo's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9527831 Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands
Jun, 2034

(7 years from now)

Active
US9107923 Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands
Jun, 2034

(7 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10093655 Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands
Jun, 2034

(7 years from now)

Active
US10421744 Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands
Jun, 2034

(7 years from now)

Active


FDA has granted several exclusivities to Juvmo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Juvmo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Juvmo.

Exclusivity Information

Juvmo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Juvmo's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 25, 2031

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Juvmo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Juvmo's family patents as well as insights into ongoing legal events on those patents.

Juvmo's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Juvmo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 23, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Juvmo Generics:

There are no approved generic versions for Juvmo as of now.

Alternative Brands for Juvmo

There are several other brand drugs in the same treatment category and using the same active ingredient (Tavapadon) as Juvmo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Tasmar Used for managing symptoms of Parkinson's disease.
Boehringer Ingelheim
Mirapex Er Used for managing symptoms of Parkinson's disease.
Impax
Rytary Used for treating Parkinson's disease and related conditions such as post-encephalitic parkinsonism and parkinsonism from carbon monoxide or manganese intoxication.
Orion Pharma
Comtan Used for treating Parkinson's disease.
Stalevo 50 Used for managing symptoms of Parkinson's disease.
Stalevo 75 Used for managing symptoms of Parkinson's Disease.
Stalevo 100 Used for managing symptoms of Parkinson's disease.
Stalevo 125 used for managing symptoms of Parkinson's Disease.
Stalevo 150 Used for managing symptoms of Parkinson's disease.
Stalevo 200 Used for managing the symptoms of Parkinson's disease.
Supernus Pharms
Osmolex Er Used for treating Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
Teva
Azilect Used for managing the symptoms of Parkinson's disease.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Tavapadon. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Abbvie
Juvmo (copackaged)






About Juvmo

Juvmo is a drug owned by Abbvie Inc. Juvmo uses Tavapadon as an active ingredient. Juvmo was launched by Abbvie in 2026.

Approval Date:

Juvmo was approved by FDA for market use on 25 September, 2026.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Juvmo is 25 September, 2026, its NCE-1 date is estimated to be 25 September, 2030.

Active Ingredient:

Juvmo uses Tavapadon as the active ingredient. Check out other Drugs and Companies using Tavapadon ingredient

Dosage:

Juvmo is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
15MG TABLET Prescription ORAL
5MG TABLET Prescription ORAL
10MG TABLET Prescription ORAL